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Antibody engineering has made it possible to design antibodies with optimal characteristics for delivery of radionuclides for
tumour imaging and therapy. A humanised divalent-Fab' cross-linked with a bis-maleimide linker referred to as humanised
divalent-Fab' maleimide was produced as a result of this design process. It is a humanised divalent antibody with no Fc, which
can be produced in bacteria and has enhanced stability compared with F(ab')2. Here we describe a clinical study in patients
with colorectal cancer using humanised divalent-Fab' maleimide generated from the anti-carcinoembryonic antigen antibody
A5B7 radiolabelled with iodine-131. Ten patients received an i.v. injection of iodine-131-labelled A5B7 humanised divalent-Fab'
maleimide, and positive tumour images were obtained by gamma camera imaging in eight patients with known lesions, and
one previously undetected lesion was identiﬁed. True negative results were obtained in two patients without tumour. Area
under the curve analysis of serial blood gamma counting and gamma camera images showed a higher tumour to blood ratio
compared to A5B7 mF(ab')2 used previously in the clinic, implying this new molecule may be superior for
radioimmunotherapy. MIRD dose calculations showed a relatively high radiation dose to the kidney, which may limit the
amount of activity that could be administered in radioimmunotherapy. However the reduction in immunogenicity was also a
major advantage for A5B7 humanised divalent-Fab' maleimide over murine versions of this antibody suggesting that humanised
divalent-Fab' maleimide should be a useful vehicle for repeated therapies.
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A5B7 is a murine monoclonal antibody raised against carcino-
embryonic antigen (CEA). A5B7 IgG and its F(ab')2 fragment
have been radiolabelled with
125I for radioimmunoguided surgery
(RIGS) and
131I for radioimmunotherapy (RIT) and radio-
immunoscintigraphy (RIS) in patients with colorectal carcinoma
(Lane et al, 1994; Theodorou, 1995). RIT has produced responses
in patients after the failure of conventional 5 ﬂuorouracil based
chemotherapy treatments (Lane et al, 1994). The maximum toler-
ated dose of
131I was 2.2 GBq m
72 with myelosuppression being
the dose-limiting factor (Lane et al, 1994). This study also showed
a more efﬁcient early tumour uptake of the F(ab')2 fragment (two-
fold increase) compared with the intact IgG.
A major limitation of RIT that has affected most clinical studies
is the production of human anti-mouse antibodies (HAMA) to
murine immunoglobulins as this often prevents re-treatment.
Anti-mouse antibodies form complexes with the tumour speciﬁc
antibody, which are rapidly cleared from the circulation so
preventing tumour localisation. Presently immunosuppressive
drugs such as cyclosporin A (CsA) are administered to reduce
HAMA formation (Ledermann et al, 1988). In the most recent
RIT study using A5B7 described by Lane et al (1994), oral admin-
istration of CsA enabled up to four repeated treatments of
131I-
A5B7. However, use of immunosuppressive drugs is not favoured
due to side effects and incomplete effectiveness.
The development of antibodies with low immunogenicity is
therefore important to allow repeated administration in RIT. Tech-
nologies to generate human antibodies such as human hybridoma
technology, transgenic or SCID-hu mice and recombinant libraries
are now available for production of high afﬁnity human antibodies
(Borrebaeck et al, 1990; Lonberg et al, 1994; Winter et al, 1994). As
an alternative, existing murine antibodies have been reconstructed
by grafting the critical portions of the antigen binding regions
(CDR’s) onto a human antibody framework (Verhoeyen et al,
1988). Clinical trials involving several humanised antibodies are
currently in various stages of progress (Emery and Adair, 1994),
and the results so far indicate that immunogenicity is in fact
reduced or completely absent using this approach (Hale and Phil-
lips, 1995; Stephens et al, 1995).
Antibody engineering has enabled the design of antibodies with
superior properties to whole IgG’s for delivery of radionuclides for
tumour imaging or therapy. We have recently performed a series of
experiments to ﬁnd the optimal characteristics of the antibody
A5B7 for RIT. A5B7 was humanised to reduce immunogenicity
and was found to target tumour effectively (Adair et al, 1992).
In addition DFM was modiﬁed to contain a single hinge thiol
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www.bjcancer.comsuitable for chemical cross-linking to form multivalent di-Fab' and
tri-Fab' molecules (Casey et al, 1996). A comparison of the proper-
ties of murine A5B7 DFM and TFM with parent F(ab')2 and IgG
was performed and kinetic analysis of antigen binding revealed that
DFM had a signiﬁcantly faster association rate than all other anti-
body forms (Casey et al, 1996). This may be a consequence of the
increased spacing or ﬂexibility of the chemical cross-linker.
Although the biodistribution data demonstrated equivalent tumour
uptake levels it was concluded that
131I -DFM due to its faster asso-
ciation rate might prove to be superior to
131I -F(ab')2 in the clinic.
In another study a re-oxidised version of humanised A5B7 hF(ab')2
was compared to chemically cross-linked hDFM; these are identical
constructs apart from the bond between the two Fab' arms. The in
vitro and in vivo stability was analysed and A5B7 hDFM proved to
have a higher afﬁnity and a signiﬁcantly improved tumour uptake
to the hF(ab')2 (Casey et al, 1995).
Although preclinical studies in nude mouse model systems
provide valuable information in selecting the most appropriate
form of antibody, pilot human investigations are necessary to assess
whether a particular antibody will be clinically useful. In this study
a batch of A5B7 hDFM, suitable for clinical purposes, was prepared
to assess the safety and tumour targeting in patients with colorectal
cancer, with the aim of the possible use of this humanised version
of A5B7 for future RIT studies. Bacterial production of hFab' was
facilitated with the use of production scale fermentation, which is
becoming an attractive alternative to mammalian expression
systems, which are relatively expensive. A5B7 hDFM is one of the
ﬁrst antibodies to be produced in E. coli for the clinic.
MATERIALS AND METHODS
Production of clinical grade hDFM and mF(ab')2
Clinical grade A5B7 hDFM was produced in accordance to the
Cancer Research Campaign (CRC) speciﬁed guidelines for produc-
tion of recombinant proteins for clinical use in the UK (Begent et
al, 1993). A5B7 murine F(ab')2 was prepared for clinical studies as
previously described by Lane et al (1994) in accordance with the
CRC Operation Manual (1986).
Fermentation of A5B7 hFab'
A5B7 hFab' was expressed in E. coli strain W3110pMRR45 as
previously described (Begent et al, 1996). Material was generated
at pilot scale using a 200 litre vessel operating in fed batch mode.
The deﬁned salts medium SM6B was used for seed and production
fermentations, and product formation was induced by switching
carbon source from glucose to lactose. Cells were harvested 20 h
post induction by continuous centrifugation. Tris/EDTA buffer
pH 7.4 was added to the cell slurry to give a ﬁnal concentration
of 50 mM EDTA. The cell suspension was then homogenised to
release Fab' from the cell periplasm and the homogenate heat trea-
ted at 468C for 16 h to remove unassembled Fab'. The extract was
then centrifuged to remove cell debris and the centrate clariﬁed
using tangential ﬂow ﬁltration on 0.2 mM membranes. The perme-
ate was made to 1 M glycine by the addition of solid glycine and
adjusted to pH 7.5 with sodium glycinate solution (50% w v
71).
Puriﬁcation of A5B7 hFab'
Puriﬁcation of hFab' was performed using streamline A
1 afﬁnity
chromatography. Streamline A
1 matrix (Pharmacia, UK) was
conditioned prior to use by washing with 6 M guanidine HCl
and equilibrated with 1 M glycine/glycinate, 25 mM NaCl pH 8.0.
The matrix was added to the sample as a slurry and allowed to
bind overnight at 48C. The slurry was packed into a column at a
ﬂow rate of 200 cm h
71 and washed with 10 column volumes
(c.v.) of equilibration buffer. The hFab' was eluted with 2–3 c.v.
of 0.1 M tri-sodium citrate/citric acid pH 3.0 at a ﬂow rate of
50 cm h
71. The hFab' containing fractions were pooled, pH
adjusted to 5.5 by addition of 2 M tris-HCl pH 8.5 and sterile
ﬁltered through a 0.2 mm ﬁlter.
Preparation of cross-linked A5B7 hDFM
Streamline A
1 puriﬁed hFab' was pooled and concentrated to
10 mg ml
71 in an Amicon stirred cell using a 10 kDa molecular
weight cut-off membrane, pre-soaked in sterile water. For reduc-
tion hFab' was dialysed into 0.1 M sodium acetate pH 6.0 with 3
buffer changes and incubated with a ﬁnal (optimised) concentra-
tion of 50 mM 2 mercaptoethylamine for 90 min at 378C with
constant agitation. The reductant was removed by buffer exchange
into 0.1 M sodium acetate pH 6.0 using a Sephadex G25 column
(70 ml: 2.6613 cm) run at a ﬂow rate of 3.0 ml min
71, collecting
2.75 ml fractions. Each fraction was analysed for the presence of
free thiol groups by performing a thiol assay as described
previously (Casey et al, 1996).
Cross-linker 1,6, bismaleimidohexane (Pierce Warriner; UK) was
added in ﬁve equal aliquots as a 1 mM solution in dimethylforma-
mide to the reduced hFab' to a ﬁnal molar ratio of 2.2:1 (Fab':
linker) and incubated with constant agitation over 30 min at 378C.
The reaction was then allowed to proceed overnight to form hDFM.
Puriﬁcation of hA5B7 DFM
Agelﬁltrationcolumn(5.06100 cm)waspackedwithapproximately
1.5 litre sephacryl S-200HR and equilibrated with 50 mM sodium
phosphate buffer. The cross-linked sample was loaded to the column
and run at a ﬂow rate of 5 ml min
71 and 2 ml fractions were
collected. Relevant fractions containing pure hDFM were pooled,
concentrated by Amicon ultraﬁltration then applied to an endotoxin
removal column as detailed previously by Casey et al (1995).
Endotoxin free material was concentrated using Amicon ultraﬁl-
tration, 0.2 mm ﬁlter sterilised and dispensed in a sterile hood into
0.5 mg aliquots which were stored at 4.08C until required.
Characterisation, toxicology and safety testing
Final aliquots of hDFM were fully characterised before and after
radiolabelling for stability and immunoreactivity by ELISA and
HPLC analysis. A biodistribution experiment with
131I-hDFM
(0.37 MBq per mouse) was performed to ensure tumour localisa-
tion in vivo of the patient material using methods described
previously (Casey et al, 1996). Toxicology (in vivo) and safety
analysis (pyrogen testing, microbiological and bacterial DNA
screening) was performed in accordance with the requirements of
the CRC regulatory committee UK (Begent et al, 1993).
Clinical trial design
A series of 10 patients were recruited for a phase I/II single centre
open clinical trial of
131I-hDFM. Eight had metastatic or recurrent
colorectal cancer with tumour CEA production conﬁrmed by
raised serum CEA concentration or by positive CEA immunohisto-
chemistry staining of biopsy specimens. Two further patients with
suspected colorectal cancer recurrence acted as negative controls.
One (patient 7) had a sacral bony metastasis suggested on a tech-
netium
99m bone scan but a subsequent biopsy did not conﬁrm
tumour recurrence. Another (patient 10) had an elevated tumour
marker CA19-9, but subsequent conventional computerised tomo-
graphy (CT), magnetic resonance (MRI), and positron emission
tomography (PET) imaging as well as laparotomy failed to conﬁrm
a recurrence. Nineteen patients were recruited for the
131I-mF(ab')2
study who had unresectable, locally recurrent or metastatic
tumours, most patients had raised CEA levels at the time of
recruitment for the study.
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gave written informed consent. The study was approved by ethics
committee and covered by ARSAC licence. The thyroid was
blocked with potassium iodide tablets (50 mg tds) for 10 days
beginning the day before the antibody scan, and potassium
perchlorate (200 mg qds for 1 day) on the day of administration.
A few hours prior to the injection of radiolabelled antibody,
patients were given an intradermal skin test injection to observe
any adverse allergic reaction to the antibody. The skin test
consisted of 10 mg antibody (0.2 ml) and a saline control. Patients
were excluded from the study if they showed a positive reaction to
the antibody (wheal 45 mm at 15 min).
131I-hDFM and mF(ab')2 (0.5 mg) were radiolabelled using the
chloramine T method to a speciﬁc activity of 0.22–0.37 MBq mg
71
and 111–185 MBq was administered to patients using an i.v.
cannula, which was ﬂushed with saline before and after radio-anti-
body infusion. Whole body planar and single photon emission
computerised tomography (SPECT) scans of the thorax and abdo-
men were performed on a Gemini 700 gamma camera at 2, 5, 24,
47 and 72 h (four patients only) post administration of radiola-
belled antibody. SPECT images were reconstructed using IGE
ﬁltered backprojection software, and corrected for decay, photon
attenuation and Compton scatter (Green et al, 1990). Scans were
analysed independently by two qualiﬁed physicians and consensus
reporting was performed in the event of a discrepancy. Patients
also had conventional conﬁrmatory CT and X-ray scanning or
appropriate MRI scanning to conﬁrm results were true positive
or negative.
Pharmacokinetic analysis and dosimetry estimates
To assess the clearance and half-life of
131I-hDFM in the circula-
tion samples of patient’s urine and whole blood (in 2 ml
heparinised tubes) were collected at each scanning time. Blood
samples (0.5 ml) were dispensed in triplicate to pre-weighed tubes
and re-weighed before counting for
131I activity in a gamma
counter. All samples were counted together, followed by standards
consisting of dilutions of the patient injectate. The percentage of
injected activity per kg (% i.a. kg
71) was evaluated and the half-
life in blood was calculated by ﬁtting data to a bi-exponential
model using the least sum of the squares regression method.
We analysed urine samples by SDS–PAGE autoradiography and
Western blotting to analyse renal clearance of
131I-hDFM.
Complete 24 h urine collection to 82 h post administration was
carried out for one patient to measure the total urinary output
of
131I-hDFM.
Additional serum and plasma samples were taken at each scan-
ning time for stability, immunogenicity and antigen binding
analysis. Stability analysis was performed by HPLC using the meth-
od previously described by Stephens et al (1995). Plasma samples
collected from patients were analysed for ability to bind to antigen.
Brieﬂy, 100 ml plasma samples were applied to microtitre wells
coated with CEA or phosphate buffer (control) in duplicate and
incubated for 1 h at room temperature on a plate shaker. The
microtitre plate was washed four times with 50 mM sodium phos-
phate buffer/0.05%Tween 20 (wash buffer) and four times with
dH2O. Each well was counted for
131I activity in a gamma counter.
An ELISA was designed to assess patients’ immune response to
hDFM, before and at 14 days and 2 months (approximately) after
injection of radiolabelled antibody. We measured the human anti-
human antibody response (HAHA) since hDFM contains a human
antibody framework. Microtitre plates (Maxisorp, Nunc) were
coated with 100 mlo fa5mgm l
71 solution of hDFM in 0.2 M
sodium carbonate buffer pH 9.6 and incubated at room tempera-
ture for 1 h. The plate was blocked overnight with 250 ml5 0m M
sodium phosphate buffer/5% BSA then washed four times with
wash buffer. A series of dilutions of test serum were prepared
and 100 ml per well in duplicate was incubated at room tempera-
ture with gentle mixing. The plate was washed as above and
incubated with 100 ml goat anti-human Fc IgM or IgG conjugated
to horseradish peroxidase (Jacksons Research Labs, USA) at 1/500
or 1/1000 respectively, and incubated for 1 h. After ﬁnal washing
the assay was detected with 3,3',5,5'-tetramethylbenzidine (TMB,
Sigma) substrate.
Dosimetry analysis of tumour and normal tissues was performed
by selecting individual 0.88 cm
3 regions of interest (ROI) taken
from SPECT images (Lane et al, 1994), with the aid of correspond-
ing CT images. These values were ﬁtted to a bi-exponential
clearance model to estimate the total residence time or area under
the curve (AUC). Values were corrected for b dose radiation (cGy)
to each tissue using the S factor for
131I (MIRD pamphlet no 11,
1975), and the MIRD absorbed dose weighting system (ICRP 60,
1990) which corrects for cross-organ doses.
RESULTS
Production of clinical grade hDFM
Large-scale fermentation of hFab' resulted in the majority of hFab'
in monomer form. Puriﬁcation using Streamline A
1 generated a
yield of approximately 85 mg.
Cross-linking resulted in 44% hDFM, with no detectable (51%)
reoxidised F(ab')2. Final puriﬁcation of hDFM from unreacted
hFab' was performed by sephadex S-200 gel ﬁltration of individual
cross-linked fractions. The yield of hDFM after gel ﬁltration was
28.5 mg. This material was passed over the endotoxin removing
column twice and analysed for presence of endotoxin. The ﬁnal
yield of concentrated endotoxin free material was 26 mg.
Characterisation, toxicology and safety testing of clinical
grade hDFM
Aliquots of hDFM were retained for characterisation analysis, toxi-
cology and assessment of contaminants. For characterisation hDFM
was analysed for purity by analytical gel ﬁltration using HPLC and
by SDS–PAGE. A single peak of the correct molecular weight was
produced demonstrating 495% of the clinical product was in the
form of hDFM.
Immunoreactivity to CEA was assessed by competition ELISA
with unmodiﬁed IgG conjugated to HRP. Similar binding to a
previous batch of hDFM (known to localise to human tumour
xenografts) was achieved, suggesting that the patient batch of
hDFM was fully immunoreactive. Immunohistochemical analysis
revealed binding of hDFM (biotinylated) to CEA producing
tumours with similar strength to murine A5B7 (biotinylated),
and retention of the high level of speciﬁcity and low cross-reactiv-
ity observed for the parent antibody.
An aliquot of hDFM was test labelled with 185 MBq
131I, with
490% incorporation. TLC analysis after desalting conﬁrmed that
98.8% of radiolabel was attached to hDFM. Antigen binding post
labelling, measured by applying a sample to a 1 ml CEA column,
produced 98% retention of antigen binding post labelling. This
was conﬁrmed by performing an ELISA with samples pre and post
labelling. Gel ﬁltration analysis after radiolabelling showed the
presence of a single peak of molecular weight 100 kDa, with no
evidence of aggregation or breakdown. A sample of
131I-hDFM
was incubated in normal human serum for 24 h (approximately)
and analysed by gel ﬁltration. The trace showed a single peak
consistent with hDFM. Radiolabelled hDFM in nude mice bearing
human colorectal tumour xenografts showed good tumour uptake
and retention, with no uncharacteristic binding to other normal
organs (Figure 1).
Toxicology showed there were no signs of disease or fever in
guinea pigs following administration of 106 the patient dose of
hDFM (unlabelled) over a 28 day observation period. The patient
material was free of pyrogens and bacterial DNA. Microbial testing
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bation for 2 days at 378C.
Blood and urine clearance
Clearance of
131I-hDFM from the circulation was monitored in
patients by counting regular blood samples (10 min, 2, 4–5, 24,
26, 48 and 72 h) and calculating the per cent injected radioactivity
(i.a.) kg
71. These data were ﬁtted to a bi-exponential model and
the best model ﬁt to the data is illustrated in Figure 2. The half-
lives for a and b phases were calculated for individual patients,
the median a-half-life was 2.12 h (range 1.3–3.1 h) and median
b-half-life was 20.3 h (range 14–26.3 h). The modelled a and b-
half-lives for the whole data set were 2.18 and 22.01 h respectively.
This is comparable to the modelled clearance for
131I-mF(ab')2 in
man with a median a-life of 0.54 h and median b-half-life of
20.7 h, also shown in Figure 2.
Samples of urine were analysed by SDS–PAGE and autoradio-
graphy. For most patients there was no evidence of breakdown
products in the urine. For three patients, low molecular weight
bands in the urine were observed, these consisted of a band of
50 and 25 kD characteristic of the molecular weight of hFab' and
light chain respectively. An immunoblot was detected with anti-
human Fab' and produced identical bands at 50 and 25 kD consis-
tent with the presence of hFab'.
Cumulative urine output of radioiodine was assessed for one
patient by collection of total urine. The majority of
131I-hDFM
was eliminated via the urine in the ﬁrst 24 h, equivalent to
20.2% of the injected activity at 23 h post collection; after which
cumulative output decreased over time (37% i.a. at 47 h, and
41% i.a. at 60 h).
Quality control
Radiolabelling of 10 individual patient aliquots of hDFM with
131I
using the chloramine T method resulted in 85–92.5% labelling
efﬁciency. Following removal of free iodine using a PD-10 column
TLC analysis revealed 97–99% incorporation to the antibody.
Samples of each radioconjugate were routinely tested for immu-
noreactivity using a CEA antigen column. Results showed that 89–
94% bound to the column compared to a non-CEA antibody
control radiolabelled with
131I which bound non-speciﬁcally 2%
of total recovered counts.
Imaging results
131I-hDFM localised to 11 out of 14 of the known sites of tumour
recurrence in eight patients known to have metastatic disease by
standard radiological techniques. In the remaining patients (7
and 10) a true negative result (i.e. conﬁrmation of no tumour)
was observed which served as normal controls. For patient 2 a
previously unidentiﬁed perineal lesion was discovered by imaging
with
131I-hDFM, the recurrence was later conﬁrmed by an MRI
scan. A summary of the results is shown in Table 1. The sensitivity
and speciﬁcity of
131I-hDFM as an imaging agent for the 10
patients in this study was 79 and 100% respectively.
An example of a SPECT image and corresponding CT scan is
illustrated in Figure 3 demonstrating positive localisation of
131I-
hDFM to a liver lesion. There is high activity in the kidneys due
to clearance as shown in the whole body image (Figure 3Cii)
and there is also evidence of unconjugated
131I manifested by the
increased activity in the stomach and upper abdomen.
Biodistribution
Quantitative assessment of tumour and measurable normal tissue
uptake of antibody by SPECT at each imaging time is shown in
Figure 4.
131I-hDFM localised to the tumour within 2 h of injec-
tion (median 4.0% i.a. kg
71) and tumour uptake reached a
maximum median level of 4.1% i.a. kg
71 5 h after injection. By
47 h the activity levels were higher in the tumour than in any other
tissue which is illustrated more clearly in Figure 5, where a tumour:
blood ratio of 2.35:1 is observed. However, due to the wide varia-
tion of per cent uptake levels in tissues for all patients, differences
in absolute uptake in different organs were not statistically signiﬁ-
cant. Four patients were imaged at 72 h post injection, and further
patient scans at this time point were not performed because the
low absolute level of activity remaining in the body meant that
gamma scanning would be of limited value for dosimetric calcula-
tions.
The highest per cent uptake was in the kidney, where a level of
up to 20.5% i.a. kg
71 was observed, indicating that a substantial
part of kidney activity is due to excretion of
131I-hDFM in urine.
This was signiﬁcantly greater than for all other tissues at 2 and
5 h after injection (P50.05 by Mann–Whitney U-test). By 24 h
median levels had fallen to 55% of the injected activity kg
71,
suggesting that most clearance occurs on the day of injection.
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Figure 1 Biodistribution of
131I-hDFM (patient batch) in nude mice bearing LS174T human colorectal tumour xenografts. Time-points at 2 h (column 1),
5 h (column 2), 24 h (column 3), 48 h (column 4) and 72 h (column 5) post injection. Results are expressed as per cent injected activity per gram of tissue,
columns are a mean of four mice and error bars represent standard deviations.
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to blood levels reﬂecting clearance of antibody from the circula-
tion. There was no evidence of non-speciﬁc uptake of
131I-hDFM
in other normal organs with measurable activity. No toxicity attri-
batable to the administration of hDFM was observed for the 10
patients in this study as assessed by the Common Toxicity Criteria
(NCI CTC, 1988).
Dosimetric analysis
The total residence time or area under the curve (AUC) of
131I-
hDFM in various tissues was calculated from the biodistribution
data. This data is expressed as tissue:blood ratios shown in Table
2. Similar AUC ratios for
131I-mF(ab')2 have also been evaluated
from a previous clinical study for comparative purposes (unpub-
lished data).
Tumour:blood ratios for hDFM were higher than for mF(ab')2.
Normal tissue distribution was similar except for kidney levels
which were three-fold higher for hDFM compared to mF(ab')2.
Levels of activity in the liver, reﬂecting hepatic clearance, are
comparatively low for both hDFM and mF(ab')2.
MIRD dosimetry
An assessment of toxicity to normal tissues was measured by esti-
mating the total absorbed dose of
131I using the MIRD schema.
Total estimates of absorbed dose are shown in Table 3. Dose to
the bone marrow per MBq injected for
131I-hDFM was similar to
that of
131I-mF(ab')2. However, total absorbed dose was signiﬁcantly
greater for
131I-hDFM compared to
131I-mF(ab')2, and this was due
to the high contribution from the kidney dose. Total dose for
131I-
hDFM was 1.67-fold greater than for
131I-mF(ab')2. This relatively
high dose to the kidneys on administration of
131I-hDFM could
therefore limit the dose that may be administered therapeutically.
Pharmacokinetics
The stability of
131I-hDFM was assessed by analysis of plasma
samples by HPLC for the presence of immune complexes and
breakdown products. Low levels of breakdown products at lower
molecular weight fractions were observed for all patients and
increased as a per cent of the total recovered counts over time
(data not shown). The calibration markers revealed that the mole-
cular weight of this peak was 51.3 kDa, and it is therefore likely
that this peak is free iodine or iodo-tyrosine, which is released
from antibody over time. At 10 min post injection 2–5% of recov-
ered activity eluted in the low molecular weight (51.5 kDa)
fraction and this increased over time to 18–26% at 72 h.
Low levels of aggregates, in the form of radioactivity appearing
in high molecular weight fractions (void volume), was observed for
some patients at later time points. This appeared to be related to
the amount of CEA antigen in the circulation measured by serum
ELISA. For two patients with relatively low levels of serum CEA
(410 mgm l
71) total aggregate formation to 26 h was 43.2%
and 47.5% up to 72 h. For seven patients with intermediate levels
of serum CEA (15–79 mgm l
71), aggregate formation to 24 h of
411.9% and 423.3% to 72 h was observed. For one patient (3)
with a very high serum CEA level (2039 mgm l
71), a large amount
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Figure 2 Modelled clearance of hDFM from blood. Blood clearance of the murine A5B7 F(ab’)2 is charted for comparison. Each diamond reﬂects an
individual data-point from which the model is derived.
Table 1 Imaging results for 10 patients administered with
131I-hDFM
Patient Serum CEA Known Imaging
no. mgl
71 metastatic disease result
1 79 Regional nodes TP nodes
Lung TP lung
Liver TP liver
2 31 CT normal TP perineum
(raised CEA) (MRI conﬁrmed)
3 2039 Lung FN lung
Liver TP liver
4 17 Liver TP liver
5 23 Regional nodes TP nodes
Liver TP liver
6 15 Local recurrence FN local recurrence
Liver TP liver
Lung FN lung
7 53 None TN bony mets
Suspected bony metastasis (benign)
8 7 Liver TP liver
9 118 Liver TP liver
10 53 None TN
Raised CA19-9 tumour marker
TP refers to true positive, TN to true negative, FN to false negative and TN to true
negative results. Serum CEA concentration (pre-dose) is shown for each patient,
normal serum CEA levels are 55 mgl
71.
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24 h of 29% was observed which decreased slightly over time to
72 h (16.4%). Overall clearance of the hDFM peak for patient 3
was slightly faster than for most of the other patients but similar
to patient 1, who had the third highest level of CEA (79 mgm l
71).
It is therefore likely that these aggregates were in the form of
immune complexes consisting of serum CEA and hDFM, which
resulted in faster clearance of antibody from the circulation.
Plasma samples were also analysed for binding to CEA coated
ELISA plates as a measure of immunoreactivity. Positive binding
(CPM) to CEA compared to control PBS wells was observed for
all samples on the day of administration. However, since a large
amount of antibody was cleared from the circulation in the ﬁrst
24 h, the dilution factor was too great to measure binding on
subsequent days post administration.
Pre-treatment and post treatment (414 day) serum samples
were routinely collected to monitor immunogenicity. There was
an increase in both IgM and IgG HAHA titre for patient 3, and
there was evidence of a minor response in IgM titre for patient
5. There was no evidence of IgM or IgG response in the remaining
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Figure 3 Imaging results for patient 5 24 h after injection of
131I-hDFM. (A) CT scan through the liver of where a liver metastasis is arrowed, (B) corre-
sponding gamma camera cross-sectional SPECT image showing localisation of
131I-hDFM to the liver metastasis and (C) corresponding whole body image (i)
anterior and (ii) posterior views. High amounts of radioactivity are shown in areas of intense colour (white–yellow). T/L=tumour/liver, H=heart, K=kidney,
S=stomach, V=vertebra, B=bladder, I=injection site, T=thyroid.
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British Journal of Cancer (2002) 86(9), 1401–1410 ã 2002 Cancer Research UKeight patients in this study. Patient 3 was known to have a very
high level of circulating CEA, and formation of immune complexes
(4200 kD) was observed by HPLC within 10 min of antibody
administration.
DISCUSSION
A combination of molecular and chemical cross-linking technologies
have been employed here to generate a new antibody construct that
has some advantages over conventional intact antibodies and their
fragments. This potentially less immunogenic humanised version
of A5B7 hFab' was the ﬁrst recombinant and cross-linked form of
A5B7 to be administered to patients. In addition this product was
also one of a very limited number of antibodies to be produced in
bacteria for the clinic (Begent et al, 1996).
It is a requirement of any regulatory organisation that new drugs
to be administered for phase I/II clinical studies be thoroughly
characterised and analysed for safety. The cell line, production
and puriﬁcation processes for A5B7 hDFM were validated and after
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Table 2 Comparisons of AUC
hDFM mF(ab')2
Tissues (n=8) (n=19)
Tumour 1.07 0.89
Liver 0.59 0.56
Lung 0.31 0.30
Kidney 2.10 0.62
Colon 0.05 –
Bladder 4.32 –
Area under the curve (AUC) estimates for hDFM, and mF(ab')2 labelled with
131Ii n
clinical studies, expressed as a tissue:blood ratio, where AUC is an integral of the
time activity curve. An integral of the bi-exponential model was calculated to time
to inﬁnity.
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deemed suitable for patient administration (Begent et al, 1993).
One of the major advantages of antibody production in bacteria
is the non-requirement for extensive testing for viruses and
mammalian DNA, which is expensive and time consuming.
Storage conditions are important to assess prior to clinical use.
However, one of the problems associated with any clinical study is
the length of time allocated to this. Short-term stability studies for
A5B7 hDFM were performed, but longer-term stability (1 year)
revealed that storage conditions (PBS pH 7.4, 48C) were sub-opti-
mal and resulted in some breakdown to hFab' (approximately
10%). Extensive stability studies of hDFM in various buffers at
different temperatures are a necessary requirement before further
clinical studies with this antibody are planned. Recent stability
studies have shown improved stability of hDFM when stored in
a lower pH buffer (pH 5.5–6) or in a lyophilised form.
In this pilot imaging study of 10 patients injected with
131I-
hDFM, at least one known tumour site was localised in all patients,
with tumour recurrence shown by conventional imaging techni-
ques. This provided clinically useful information in either
conﬁrming patients had recurrent disease, identifying a new lesion
(one patient), or conﬁrming there was no disease (two patients).
The three false negative ﬁndings were in two patients. In one
patient a lung metastasis and local recurrence and in the other a
lung metastasis, were not disclosed by antibody imaging but were
seen by CT.
Blood clearance kinetics deﬁned in all 10 patients demonstrated
similar blood clearance and half-lives to mF(ab')2 in man. This was
surprising as direct comparisons for murine parent antibodies and
engineered chimeric or humanised versions of the same antibody
have frequently resulted in prolonged half-lives (LoBuglio et al,
1989). However, a direct comparison of humanised antibody frag-
ments with the murine equivalent has not been carried out
previously. Also half-life is known to be dependent on protein
dose, resulting in an increased clearance rate of lower doses of
the same antibody (Stephens et al, 1995). This may be particularly
relevant when circulating antigen may be present as in this case. A
relatively high dose of A5B7 mF(ab')2 (10 mg per patient) was
administered to patients for RIT compared to the imaging dose
of 0.5 mg hDFM administered in this study. Therefore a longer
circulating half-life may be observed for higher therapy doses of
hDFM.
Some studies have attempted to address the relationship of
circulating antigen and half-life (Davidson et al, 1991; Pimm,
1995; Behr et al, 1996). In one study, data from 275 patients was
analysed, and results implied that antibodies administered to
patients with normal plasma CEA (55 mgl
71) had longer half-
lives than in patients with CEA levels in excess of 10 mgl
71 (Behr,
1996). In this study only two patients had CEA levels 55 mgl
71
(patients 7 and 10) and their plasma or blood half-life was not
signiﬁcantly different to the other patients. However for one
patient (3) with very high levels of CEA (2039 mgl
71) formation
of antibody complexes was observed by HPLC soon after antibody
administration. This resulted in faster clearance of hDFM from the
circulation and a corresponding shorter b-half-life in blood of 14 h
compared to the median of 20.3 h. Low tumour uptake levels,
especially at early time points (2 h:0.9% i.a. kg
71, median value
4%), may have been the result of more rapid clearance of hDFM
from the circulation. Despite this however, positive tumour
imaging was reported.
The biodistribution of
131I-hDFM was extensively studied by
gamma camera imaging at various scanning times to enable quan-
tiﬁcation of absorbed dose to radiosensitive organs. The results
were compared to similar clinical data using
131I-mF(ab')2 (Lane
et al, 1994) in an attempt to assess whether
131I-hDFM would be
a better candidate for RIT studies. AUC (Table 2) estimates
revealed a higher overall tumour to blood ratio for hDFM (1.07)
compared to mF(ab')2 (0.89) which is desirable for RIT.
AUC (Table 2) and MIRD (Table 3) estimates indicated a simi-
lar biodistribution and clearance of both fragments except for high
kidney uptake of
131I-hDFM. In nude mice experiments we have
observed similar biodistribution patterns including kidney uptake
for
131I-labelled hDFM, mDFM and mF(ab')2, implying that this
high kidney uptake of
131I-hDFM was speciﬁc only to man.
It is unclear why there are major differences in kidney uptake of
hDFM and mF(ab')2; the altered clearance pattern of similar sized
molecules suggests that other factors such as shape and charge may
also inﬂuence the rate of clearance via the kidney (Sumpio and
Hayslett, 1985). The presence of the thio-ether bond could in some
way affect the clearance of hDFM leading to non-speciﬁc uptake by
the renal tubules. High stability of the thio-ether bond could result
in slower catabolism resulting in a longer kidney residence time.
We observed breakdown of hDFM to hFab' occurring in the
kidney’s as analysed by SDS–PAGE and autoradiography of urine
samples, indicating renal catabolism occurs. Further experiments
were performed to assess whether hDFM cross-reacted with human
kidney samples from four individuals, by performing immunohis-
tochemistry experiments. These ﬁndings showed no non-speciﬁc
binding of hDFM to normal human kidney, indicating there was
no binding to a renal antigen.
Dosimetry estimates indicate that the dose-limiting organ for
hDFM is the kidney, and if hDFM is to be considered for RIT it
would obviously be desirable to reduce kidney levels of activity.
A promising option is to attach polyethylene glycol (PEG) to
hDFM which in a recent study in nude mice bearing human color-
ectal tumour xenografts was shown to increase the circulatory half-
life resulting in higher tumour uptake levels and a lower absorbed
dose to the kidney (Casey et al, 2000).
The red bone marrow is highly radiosensitive and myelosup-
pression often limits the total dose that may be administered
therapeutically (Siegel et al, 1990). It is therefore important to
assess the toxicity to bone marrow and other radiosensitive
organs, such as the kidney, in low-dose clinical studies such as
the one described here, to predict possible toxicity on administra-
tion of higher doses. Dose to the red bone marrow is usually
assumed to be proportional to the blood dose, where marrow
dose is equivalent to blood dose60.4 (Siegel et al, 1990). The
maximum tolerated doses (MTD) for radiosensitive organs such
as red bone marrow and kidney have been evaluated by conven-
tional radiotherapy studies to be 5200 and 51500 cGy
respectively (Fawwaz et al, 1986). Therefore, by considering these
limits, the maximum tolerated activity can be estimated using the
MIRD dosimetry calculations for
131I-hDFM and
131I-mF(ab')2
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Table 3 b absorbed dose calculations
TIssues hDFM mF(ab')2
Bone (red marrow) 0.068 0.076
Bone surface 0.041 0.048
Breast 0.016 0.042
Gonads 0.054 0.016
Lung 0.103 0.258
Thyroid 0.004 0.010
Colon 0.097 0.015
Liver 0.120 0.141
Stomach 0.051 0.037
Kidney 1.860 0.805
Total dose 2.414 1.448
Estimated absorbed doses of b-radiation using the MIRD schema (MIRD Pamphlet no
11, 1975, and MIRD weighting system ICRP 60, 1990) derived from the quantitative
data generated from blood counting and SPECT imaging of the 10 patients receiving
131I-hDFM. The data was corrected for absorbed dose contributions from adjacent
organs using the MIRD weighting system for individual tissue (for the standard
70 kg man) and expressed as mGy MBq
71. For comparative purposes MIRD dose
estimates for 19 patients treated with mF(ab')2 are also included in this table.
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tolerance would be: 1500/0.186=8.06 GBq for
131I-hDFM, and
1500/0.0805=18.6 GBq for
131I-mF(ab')2; and for maximum toler-
ance to the red marrow and bone surface: 200/0.0109=18.4 GBq
for
131I-hDFM, and 200/0.0124=16.1 GBq for
131I-mF(ab')2. This
implies that the dose limiting organ for hDFM is the kidney
and the bone marrow for mF(ab')2. However, these are estimated
doses, and an organised dose escalation study involving detailed
toxicity assessment is required before a true MTD is obtained.
The MTD for A5B7
131I-mF(ab')2 has previously been shown to
be approximately 3.29 GBq m
2 (Lane et al, 1994), implying that
the MIRD weighting for red marrow is underestimated, as toxicity
was observed at much lower levels than was anticipated using the
MIRD estimates.
Although there is at present little data to suggest renal damage
after RIT, impairment of renal function has been observed with
whole abdominal irradiation in patients given doses 420 Gy.
However with similar or higher doses administered in a fractio-
nated manner there has been no evidence of renal toxicity up to
5 years after treatment (Irwin et al, 1996). Although the toxicity
levels of external whole body irradiation and RIT cannot be
directly compared, this implies that a fractionated approach to
administration of hDFM may also be worth considering.
In the present study only one patient elicited a positive immune
response 2 weeks after
131I-A5B7 hDFM injection. However, this
patient also had a level of high circulating CEA and evidence of
immune complexes soon after antibody injection. Immune
complexes may cause an increase in the propensity to produce
anti-antibodies due to increased recognition by cells of the immune
system. This is effectively similar to the natural host defence
mechanism by the immune system on attack by a foreign antigen
when host antibodies complex with antigen and present the antigen
as foreign to cells of the immune system (Roitt, 1991). A similar
mechanism may occur here when circulating host antigen
complexes with foreign antibody.
There have been only a few reports describing the immunogeni-
city of humanised antibodies in clinical studies, and as yet no
studies involving humanised fragments. Hale et al (1988) reported
that lymphoma patients treated with multiple doses of this anti-
body showed no antibody response to a humanised version of
CAMPATH-1H. In a further study CAMPATH-1H was adminis-
tered to rheumatoid arthritis patients repeatedly over 10 days.
No immune response was reported following this ﬁrst course of
treatment but following the second course of treatment three out
of four patients showed a detectable immune response. However
this immune response was not characterised. In another study
the humanised antibody CDP571 was administered as a single dose
ranging from 0.1–10 mg kg
71 to human volunteers (Stephens et
al, 1995). At low doses a weak immune response of IgM anti-idio-
type was detectable and at higher doses responses were lower or
undetectable. In a pilot imaging study none of the four patients
with B-cell lymphomas receiving 2 mg of the humanised LL2 anti-
body developed an immune response (Juweid et al, 1995). In a
further small study, eight patients received the anti-CEA huma-
nised hMN-14 antibody (0.5–20 mg) and the immune response
was measured in ﬁve patients (Sharkey et al, 1995). Four of these
patients received 2–3 injections and two received high protein
doses (10–20 mg). An immune response was not recorded for
any of these patients during the 4–5 week follow up period.
These initial results suggest that humanised antibodies are less
immunogenic than murine antibodies, especially at higher concen-
trations, and therefore should enable repeated administration.
However, all of the above studies, including the one described here,
involved small numbers of patients, low doses and usually only one
injection of humanised antibody. Further analysis is necessary to
study the immune response of humanised antibodies and frag-
ments in larger clinical studies. If hDFM is to be considered for
RIT, studies must be performed to determine whether the immu-
nogenicity of hDFM will remain low at higher doses and after
multiple injections. Furthermore the potential immunogenicity of
the maleimide linker is a signiﬁcant issue. Clearly, in future clinical
studies involving higher doses of antibodies or fragments contain-
ing the maleimide cross-linker characterisation of the immune
response is essential. There have to date been no reported studies
to indicate that the maleimide linker is immunogenic in animals
or patients.
It is our aim to design an antibody construct based on the IgG
A5B7, which has optimal properties for RIT. We have shown in
this pilot clinical study that A5B7
131I-hDFM proved to be effective
in targeting tumours in all patients with known lesions with a
median maximum of 4.1% of the total injected activity. The area
under the curve data revealed a higher estimated tumour to blood
ratio for A5B7 hDFM compared to A5B7 mF(ab')2 implying it will
be superior for RIT. The only problem that did not become evident
until this clinical trial was performed was the high level of kidney
uptake in patients. We have further optimised DFM by the addi-
tion of PEG, which in our nude mouse model showed superior
tumour uptake levels and lower kidney toxicity (Casey et al, 2000).
In conclusion, we have demonstrated that it is possible to engi-
neer superior antibody products for optimal tumour targeting. The
clinical study revealed improved tumour localisation and lower
immunogenicity for hDFM compared to mF(ab')2; therefore indi-
cating that hDFM should prove to be our optimal form of A5B7
anti-CEA antibody for future RIT.
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